Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?

Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?

Blog Article

Dasatinib is a tyrosine vivobook x515 kinase inhibitor used for treatment of some specific types of leukaemia.The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional.No case has been reported beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in such scenario.The underlying mechanism is not currently clear.

We describe a woman ferrofish a32pro on dasatinib treatment for more than 10 years who developed chylothorax.Drug withdrawal resolved the chylous pleural effusion.We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.